Corvus Pharmaceuticals/$CRVS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
- Ticker
- $CRVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 37
- Headquarters
- South San Francisco, United States
- Website
- www.corvuspharma.com
CRVS Metrics
BasicAdvanced
$887M
-
-$0.72
-
-
Price and volume
Market cap
$887M
52-week high
$26.95
52-week low
$6.39
Average daily volume
1.1M
Financial strength
Current ratio
13.383
Quick ratio
13.163
Long term debt to equity
0.001
Total debt to equity
0.003
Profitability
EBITDA (TTM)
-67.569
Management effectiveness
Return on assets (TTM)
-27.83%
Return on equity (TTM)
-45.92%
Valuation
Price to book
4.27
Price to tangible book (TTM)
4.27
Price to free cash flow (TTM)
-19.67
Free cash flow yield (TTM)
-5.08%
Free cash flow per share (TTM)
-0.536
Growth
Earnings per share change (TTM)
30.50%
3-year earnings per share growth (CAGR)
4.21%
10-year earnings per share growth (CAGR)
-13.24%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
Analyst projections of the future price of Corvus Pharmaceuticals stock.
Bulls say / Bears say
In the 24-patient, eight-week Phase 1 atopic dermatitis cohort, 75% of soquelitinib patients achieved EASI-75 versus 20% on placebo, with no serious adverse events reported. If confirmed in the larger Phase 2 trial, this could support a new oral treatment option. (Corvus Pharmaceuticals, GlobeNewswire)
In an early ALPS study, all three patients completed a year of treatment, stopped background medicines including steroids and reported improved symptoms, with no grade 3 or 4 adverse events. This offers a promising signal that soquelitinib may have value beyond cancer and skin disease. (GlobeNewswire)
Soquelitinib is being tested in a 150-patient Phase 3 trial for relapsed or refractory peripheral T-cell lymphoma, where the company says there are no fully FDA-approved treatments. A positive result could address an unmet need in a serious cancer. (GlobeNewswire)
The atopic dermatitis result rests on just 12 patients receiving soquelitinib in the strongest Phase 1 cohort, so the 75% response rate may not hold in larger studies. The 200-patient Phase 2 trial has yet to report, with topline results expected in Q3 2027. (Corvus Pharmaceuticals, GlobeNewswire)
The Phase 3 lymphoma study faces a near-term go-or-stop test: an independent committee is expected to conduct a futility review in Q1 2027, and Corvus will disclose only whether the trial continues, not the underlying efficacy or safety data. The event-driven timing could also shift. (The Motley Fool)
Corvus's Q3 net loss nearly doubled year on year to $20.3 million as it expands clinical development. Its $202.9 million cash balance provides runway into Q2 2028, but continued trial spending before any product revenue leaves future funding and potential shareholder dilution as risks. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
Upcoming events
No upcoming events
CRVS News
AllArticlesVideos
Funds containing CRVS
Fund name | Fund size | $CRVS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.